AUTHORS
Henri C. Hupe, MD, Sophie Pietzka2, Rintaro Kubo3, Thomas Francke4, Lara Hövel, MD5, Anna Herba6, Michael Stadler7, Arnold Ganser I, MD8, Michael Heuser, MD9, Florian H. Heidel IV, MD10, Felicitas R Thol, MD11
AFFILIATIONS
1 Hannover Medical School, Hannover, Germany
2 Hannover Medical School, Hannover, Germany
3 Hannover Medical School, Hannover, Germany
4 Hannover Medical School, Hannover, Germany
5 Hannover Medical School, Hannover, Germany
6 Hannover Medical School, Hannover, Germany
7 Hannover Medical School, Hannover, Germany
8 Hannover Medical School, Hannover, Germany
9 University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle, Germany
10 Hannover Medical School, Hannover, Germany, Leibniz Institute on Aging, Fritz Lipmann Institute, Jena, Germany
11 Hannover Medical School, Hannover, Germany
ABSTRACT
Introduction: Central nervous system (CNS) involvement in acute myeloid leukemia (AML) is a rare extramedullary manifestation that may occur at diagnosis or relapse. Routine CNS evaluation is not recommended in adults with AML and is generally reserved for patients with neurological symptoms, while evidence regarding the risk factors and clinical and molecular characteristics of CNS involvement remains limited. We therefore performed a comprehensive clinical and molecular characterization of AML patients with CNS involvement in a large single-center cohort.
Methods: We retrospectively analyzed AML patients (≥18 years) with cytomorphologically confirmed CNS involvement treated at our institution between 1994 - 2024. Targeted next-generation sequencing using a custom myeloid panel (up to 46 genes) was performed on mononuclear cells from bone marrow, peripheral blood, and cerebrospinal fluid, at diagnosis and relapse. Ultrahigh-sensitivity amplicon-based NGS-MRD was performed as previously described (Thol et al., Blood, 2018). Clinical and molecular characteristics were compared with a previously published institutional reference cohort of AML patients undergoing allogeneic hematopoietic stem cell transplantation (alloHCT) in first or second complete remission (CR) excluding patients with extramedullary disease (Thol et al., Blood, 2018).
Results: We identified 60 AML patients with cytomorphologically confirmed CNS involvement. The median age at diagnosis was 46 years (range, 17–76), and 43 patients (72%) were male. Most patients (n=57, 95%) received intensive therapy, and 52 patients (87%) underwent alloHCT. CNS involvement occurred as isolated disease in 25 patients (42%), concomitant with bone marrow involvement in 30 patients (50%), and both as isolated and concomitant disease during the disease course in 5 patients (8%). Multiple CNS relapses occurred in 12 patients (20%). Extramedullary disease outside the CNS was observed in 22 patients (37%), most frequently involving the skin (n=6, 10%), soft tissue (n=5, 8%), lymph nodes (n=5, 8%), and spine (n=3, 5%).
Baseline characteristics were generally comparable between patients with CNS involvement and the matched institutional reference cohort (n=88). The reference cohort was numerically older (median age, 53 years [range, 19–70]; p=0.29) and less frequently male (59%; p=0.09). Compared with the reference cohort, patients with CNS involvement more frequently had a myelomonocytic phenotype (FAB M4/M5; 62% vs. 32%; p<0.01), higher white blood cell counts at diagnosis (median, 23.2 vs. 8.2 10^9/L; p=0.04), were enriched for inv(16) (10% vs. 1%; p=0.02) and showed a trend toward more frequent 11q23 abnormalities (16.7% vs. 6.8%; p=0.07). The frequency of complex karyotypes was similar between cohorts (13% vs. 8%; p=0.41), whereas secondary AML was less common in the CNS cohort (10% vs. 27%; p=0.01). Myeloid panel sequencing at diagnosis was available for 45 AML patients with CNS involvement and showed enrichment of NRAS (p=0.02) and KIT mutations (p=0.02), whereas RUNX1 (p=0.03), BCOR (p<0.01), and STAG2 (p=0.02) mutations were more frequent in the reference cohort.
Forty-one of 52 patients (79%) with CNS involvement underwent alloHCT in CR. Overall survival (OS) for these patients was numerically shorter than that of the reference cohort but did not differ significantly (HR 0.67, 95% CI 0.38 – 1.18, p=0.22). Pre-transplant NGS-MRD assessment was available in 12 of 24 patients who subsequently developed CNS relapse after alloHCT. Residual disease was detected in 7 of 12 patients (58%). Notably, all MRD-negative patients developed isolated CNS relapse, whereas MRD-positive patients experienced both isolated and concomitant CNS/systemic relapse.
Conclusion: This study represents the largest clinically and molecularly characterized cohort of AML patients with CNS involvement to date. CNS involvement was associated with a myelomonocytic phenotype, high white blood cell counts at diagnosis, inv(16), NRAS/KIT-mutations and a lower frequency of secondary AML. Among patients who underwent alloHCT in CR, OS did not differ significantly to that of the reference cohort without extramedullary disease. Pre-transplant NGS-MRD status may be related to the subsequent pattern of CNS relapse, with MRD-negative patients predominantly developing isolated CNS relapse. These findings may improve risk stratification and guide future surveillance and preventive strategies.
DISCLOSURES
Henri C. Hupe, MD: No relevant conflicts of interest to declare.